US FDA awards Clarity Pharma's novel prostate cancer PET scan imaging compound fast track status
Clarity Pharmaceuticals (ASX:CU6) has revealed it's received fast track status from the US FDA for its prostate cancer imaging compound designed for PET scans.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
REF | Bye bye Reverse Corp | 14/08/22 | 2 | 1.2K | |||
|
|||||||
REF | Shareholder meeting | 05/07/22 | 6 | 2.0K | |||
|
|||||||
REF | Half yearly report | 10/05/22 | 0 | 369 | |||
|
|||||||
REF | Unlisted public company | 03/02/22 | 4 | 1.6K | |||
|
|||||||
REF | Ann: Notice of Annual General Meeting/Proxy Form | 20/01/22 | 11 | 2.0K | |||
|
|||||||
REF | News: REF Reverse Corp Says Acknowledged ASX's Decision To Remove REF From Asx | 17/01/22 | 0 | 249 | |||
|
|||||||
REF | Ann: Market Update | 17/01/22 | 0 | 443 | |||
|
|||||||
REF | Ann: Removal from Official List | 17/01/22 | 1 | 607 | |||
|
See All Discussions